BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 27c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.40), $0.27 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $3.26 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst